Drug Development

After a strategic reset, Australian biopharma Immuron reports record sales and a stronger cash position, pivoting to partner its high-value drug candidates.

A landmark UCSF study has mapped the molecular machinery of autism, revealing convergent pathways. This isn't just a breakthrough for ASD; it's a new model for drug discovery.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

As a deadly Bundibugyo ebolavirus outbreak grips the DRC, a $16.5M CEPI investment in Egypt's Minapharm marks a pivotal shift toward African health sovereignty.

Xeris Biopharma's XP-8121 aims to solve a key problem in hypothyroidism. Can this weekly injection capture a multi-billion dollar market from daily pills?

A German biotech's novel drug just won a key FDA designation, a strategic move that could redefine the limits of liver surgery and cancer treatment.

JATT III Acquisition Corp's $60M IPO isn't just another SPAC. It’s a calculated bet by a proven team on the future of AI in drug discovery. But does it signal a new era for biotech M&A?

Allegheny Health Network and START's new partnership isn't just a local win; it's a blueprint for a more accessible, patient-centric future in oncology.

A small biophysics firm unveils promising data for its at-home headset using magnetic fields to treat Long COVID, heralding a potential shift from pharma to biophysics.

A landmark $1.5B+ deal for a Chinese drug marks a major global shift. Haisco's innovative partnership with a US venture is reshaping biotech collaboration.

The 72-year MDA-IAFF partnership has a new, urgent mission: investigating why firefighters face a heightened risk of ALS. Here's what's at stake.

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

With a new patent, a bold asset pivot, and a top-tier banking partner, PharmAla Biotech is signaling a new phase of commercial maturity in psychedelic medicine.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

A new AI-designed eye drug gets clinical trial clearance, validating Matwings' iterative platform and signaling a major shift in biopharma R&D strategy.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.